RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nxera Pharma Co Stock

Nxera Pharma Co Revenue 2024

Nxera Pharma Co Revenue

37.45 B JPY

Ticker

4565.T

ISIN

JP3431300007

WKN

A0B7EK

In 2024, Nxera Pharma Co's sales reached 37.45 B JPY, a 193.32% difference from the 12.77 B JPY sales recorded in the previous year.

The Nxera Pharma Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2026e43.3322,30
2025e41.5823,24
2024e37.4525,81
202312.7775,70
202215.5794,05
202117.7194,73
20208.8491,39
20199.7391,25
20182.8788,34
20176.96138,95
201618.951,13
20158.1599,95
20143.67263,25
20132.0787,83
20121.9683,36
20110.8670,53
20100.7292,89
20090.9286,09
20080.1520,26
20070.7182,79
20060.7433,65
20050.4212,26
20040.2494,67

Nxera Pharma Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nxera Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nxera Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nxera Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nxera Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nxera Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nxera Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nxera Pharma Co’s growth potential.

Nxera Pharma Co Revenue, EBIT and net profit per share

DateNxera Pharma Co RevenueNxera Pharma Co EBITNxera Pharma Co Net Income
2026e43.33 B undefined0 undefined4.55 B undefined
2025e41.58 B undefined0 undefined5.2 B undefined
2024e37.45 B undefined0 undefined2.49 B undefined
202312.77 B undefined-10.46 B undefined-7.19 B undefined
202215.57 B undefined2.81 B undefined382 M undefined
202117.71 B undefined6.91 B undefined1.02 B undefined
20208.84 B undefined854 M undefined1.48 B undefined
20199.73 B undefined960 M undefined1.43 B undefined
20182.87 B undefined-5.54 B undefined-5.98 B undefined
20176.96 B undefined-2.46 B undefined-2.65 B undefined
201618.9 B undefined12.13 B undefined9.31 B undefined
20158.15 B undefined930 M undefined-1.43 B undefined
20143.67 B undefined1.03 B undefined516 M undefined
20132.07 B undefined682 M undefined1.53 B undefined
20121.96 B undefined-953 M undefined-647 M undefined
2011862 M undefined-1.96 B undefined-1.95 B undefined
2010717 M undefined-1.88 B undefined-1.87 B undefined
2009920 M undefined-1.86 B undefined-1.77 B undefined
2008153 M undefined-3.67 B undefined-3.94 B undefined
2007709 M undefined-6.27 B undefined-6.5 B undefined
2006740 M undefined-6.65 B undefined-6.24 B undefined
2005416 M undefined-4.41 B undefined-4.18 B undefined
2004244 M undefined-1.75 B undefined-1.82 B undefined

Nxera Pharma Co stock margins

The Nxera Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nxera Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nxera Pharma Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nxera Pharma Co's sales revenue. A higher gross margin percentage indicates that the Nxera Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nxera Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nxera Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nxera Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nxera Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nxera Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nxera Pharma Co Margin History

Nxera Pharma Co Gross marginNxera Pharma Co Profit marginNxera Pharma Co EBIT marginNxera Pharma Co Profit margin
2026e75.7 %0 %10.49 %
2025e75.7 %0 %12.5 %
2024e75.7 %0 %6.64 %
202375.7 %-81.94 %-56.34 %
202294.05 %18.06 %2.45 %
202194.73 %39.01 %5.74 %
202091.39 %9.66 %16.73 %
201991.25 %9.87 %14.72 %
201888.34 %-193 %-208.11 %
201775.7 %-35.4 %-38.16 %
201675.7 %64.16 %49.26 %
201599.95 %11.41 %-17.57 %
201475.7 %28.11 %14.06 %
201387.83 %32.95 %73.72 %
201283.36 %-48.65 %-33.03 %
201170.53 %-227.61 %-226.68 %
201092.89 %-261.65 %-261.09 %
200986.09 %-201.63 %-192.28 %
200820.26 %-2,397.39 %-2,574.51 %
200782.79 %-884.34 %-917.35 %
200633.65 %-898.78 %-843.24 %
200512.26 %-1,059.38 %-1,003.85 %
200494.67 %-718.44 %-745.9 %

Nxera Pharma Co Aktienanalyse

What does Nxera Pharma Co do?

The Sosei Group Corp. is a Japanese company that operates in the fields of pharmaceutical research and development. It was founded in 1990 as Photonamic GmbH & Co KG in Munich, Germany, before being renamed Sosei Co. Ltd. in 2003. The company is headquartered in Tokyo, Japan, and operates research and development facilities in Japan, the United Kingdom, and Denmark. Sosei is involved in several significant drug development projects and has produced some successful products in the past. Business model: The main focus of the Sosei Group Corp. is the research and development of pharmaceuticals. Its primary business model is to be involved in the entire value chain of drug development, from the discovery and characterization of new drug candidates to clinical development and regulatory approval. In order to attract partners in the pharmaceutical and biotech industry, the company offers its core competencies in drug research and development, including optimizing drug candidates and conducting clinical trials. Partnerships can be structured in the form of strategic alliances, licensing fees, milestone payments, and profit sharing. Divisions: The Sosei Group Corp. divides its activities into three main divisions: 1. Sosei Heptares: The company is a leading player in G-protein-coupled receptor (GPCR) research and development. GPCRs are a class of membrane proteins involved in regulating signal transduction processes and are of significant importance in drug development. Sosei Heptares provides its expertise and technology platform to third parties for developing new drugs targeting GPCR. 2. Sosei R&D: Sosei R&D focuses on the discovery and development of new drug candidates in various therapeutic areas, including inflammation, oncology, pain, respiratory, and mental disorders. The company utilizes its proprietary technology platform, which includes computer-aided design and synthesis optimization, to identify and develop new drugs. 3. Sosei CMC: The Sosei CMC department is responsible for developing customized processes for manufacturing pharmaceuticals. It encompasses all aspects of drug manufacturing, from formulation to manufacturing techniques. The department also works closely with other departments of the company to ensure that the drug products meet the highest quality and safety standards. Products: Sosei has developed and brought to market some successful drugs in the past. These include medications such as: 1. NVA237 (glycopyrronium bromide): An inhalation medicine for the treatment of chronic obstructive pulmonary disease (COPD). 2. QVA149 (indacaterol/glycopyrronium bromide): Another inhalation medicine approved for the treatment of COPD. 3. Sovodakso (GSK-491876): A drug candidate developed in partnership with GlaxoSmithKline (GSK) currently under investigation in phase III clinical trials for the treatment of schizophrenia. 4. Aclidinium bromide: An inhalation medicine for the treatment of COPD, developed in partnership with Almirall. In summary, the Sosei Group Corp. is a leading player in pharmaceutical research and development. The company focuses on developing novel drugs for the treatment of a variety of diseases and works closely with partners in the pharmaceutical and biotech industry. With its extensive knowledge and technological expertise, Sosei is one of the few companies capable of overcoming the challenges in drug development. Nxera Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Nxera Pharma Co's Sales Figures

The sales figures of Nxera Pharma Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Nxera Pharma Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Nxera Pharma Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Nxera Pharma Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Nxera Pharma Co stock

How much revenue did Nxera Pharma Co generate this year?

Nxera Pharma Co has achieved a revenue of 37.45 B JPY this year.

How much was the turnover of the company Nxera Pharma Co compared to the previous year?

The revenue of Nxera Pharma Co has increased by 193.32% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Nxera Pharma Co?

The revenue of Nxera Pharma Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Nxera Pharma Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Nxera Pharma Co so important for investors?

The revenue of Nxera Pharma Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Nxera Pharma Co pay?

Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.21 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Nxera Pharma Co?

The current dividend yield of Nxera Pharma Co is 0.21 %.

When does Nxera Pharma Co pay dividends?

Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nxera Pharma Co?

Nxera Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Nxera Pharma Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nxera Pharma Co located?

Nxera Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nxera Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.

When did Nxera Pharma Co pay the last dividend?

The last dividend was paid out on 6/24/2015.

What was the dividend of Nxera Pharma Co in the year 2023?

In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.

In which currency does Nxera Pharma Co pay out the dividend?

The dividends of Nxera Pharma Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nxera Pharma Co

Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.